Anti-CGRP Migraine Drugs Linked to Pregnancy Loss Risk
New research suggests a higher risk of early pregnancy loss for those using specific anti-CGRP migraine medications.
Updated on Oct. 21, 2026 in Pregnancy
A new study published in JAMA Neurology indicates an association between exposure to anti-CGRP monoclonal antibody medications for migraine and an increased risk of early pregnancy loss. The research compared pregnancy outcomes for those using these specific migraine treatments against those taking propranolol during the first 20 weeks of gestation.
Why it matters
Researchers identified a 4.2 percentage point absolute increase in the risk of pregnancy loss for those exposed to anti-CGRP antibodies compared to those taking propranolol. This is significant because CGRP plays a documented role in vascular regulation, placental development, and uteroplacental blood flow, which are vital for early pregnancy.
The study analyzed 7,579 pregnancies occurring between 2018 and 2021, recording 1,862 total spontaneous abortions. Results showed a 28.6% abortion rate among those using anti-CGRP antibodies compared to 12.8% for those using propranolol.
The players
NICE
The National Institute for Health and Care Excellence provides guidance on health technologies and preventative treatments.
JAMA Neurology
A peer-reviewed medical journal that publishes research on neurological disorders and related therapeutic interventions.
The details
Researchers followed pregnancy outcomes up to the 20th week to compare the effects of different migraine treatments. The study focused on anti-CGRP monoclonal antibody medicines, which are designed to block specific proteins involved in pain signaling but also have physiological functions in blood vessel regulation and implantation. Safety concerns arise because these proteins are necessary for maintaining healthy uteroplacental blood flow during the earliest stages of fetal development.
Timeline
2018-2021: The study period for analyzed pregnancy data.
2020: NICE recommended fremanezumab for chronic migraine prevention.
2023: NICE recommended rimegepant.
October 12, 2026: Study findings published in JAMA Neurology.
The Home Front
The findings complicate the current landscape for managing chronic migraines, which has seen increased availability of CGRP-targeting therapies following NICE recommendations. This research prompts a re-evaluation of treatment protocols for those who are pregnant or planning to conceive.
If you are currently pregnant or planning to conceive and use anti-CGRP migraine medications, consult your physician to discuss your treatment plan. Do not discontinue prescribed medications without first speaking with a medical professional, as managing your health during pregnancy requires expert guidance.
The takeaway
This study underscores the importance of discussing reproductive health goals with your healthcare provider when choosing between different migraine treatment options. Always maintain an updated list of your current medications and dosages to facilitate informed consultations during your medical visits.
Further reading
For more information on family health considerations, explore our Pregnancy section.
Source note: This article includes information reported by The Pharmaceutical Journal.
